BRPI0702847A - temozolomide unit dosage forms - Google Patents

temozolomide unit dosage forms

Info

Publication number
BRPI0702847A
BRPI0702847A BRPI0702847-4A BRPI0702847A BRPI0702847A BR PI0702847 A BRPI0702847 A BR PI0702847A BR PI0702847 A BRPI0702847 A BR PI0702847A BR PI0702847 A BRPI0702847 A BR PI0702847A
Authority
BR
Brazil
Prior art keywords
dosage forms
unit dosage
temozolomide
relates
methods
Prior art date
Application number
BRPI0702847-4A
Other languages
Portuguese (pt)
Inventor
Jacqueline Rose Bersch
Mark Manzo
Sumant Ramachandra
Original Assignee
Schering Corportation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corportation filed Critical Schering Corportation
Publication of BRPI0702847A publication Critical patent/BRPI0702847A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Abstract

FORMAS DE DOSAGEM UNITáRIA DE TEMOZOLOMIDA. A presente invenção refere-se a formas de dosagem unitária de temozolomida. Estas formas de dosagem unitária são particularmente adequadas para reduzir o incómodo das pílulas e aumentar a colaboração do paciente. A invenção também se refere a métodos para tratar distúrbios proliferativos em um paciente com estas formas de dosagem unitária. A invenção refere-se adicionalmente a kits compreendendo estas formas de dosagem unitária.UNITARY METHODS OF TEMOZOLOMIDE. The present invention relates to temozolomide unit dosage forms. These unit dosage forms are particularly suitable for reducing pill discomfort and increasing patient collaboration. The invention also relates to methods for treating proliferative disorders in a patient with such unit dosage forms. The invention further relates to kits comprising these unit dosage forms.

BRPI0702847-4A 2006-06-26 2007-06-25 temozolomide unit dosage forms BRPI0702847A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26
PCT/US2007/014761 WO2008002544A2 (en) 2006-06-26 2007-06-25 Unit dosage forms of temozolomide

Publications (1)

Publication Number Publication Date
BRPI0702847A true BRPI0702847A (en) 2008-04-01

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0702847-4A BRPI0702847A (en) 2006-06-26 2007-06-25 temozolomide unit dosage forms

Country Status (13)

Country Link
EP (1) EP1901740A2 (en)
JP (1) JP2008534692A (en)
KR (2) KR20100055543A (en)
CN (1) CN101309686A (en)
AR (1) AR061618A1 (en)
AU (1) AU2007221979A1 (en)
BR (1) BRPI0702847A (en)
CA (1) CA2610439A1 (en)
CL (1) CL2007001864A1 (en)
NO (1) NO20074913L (en)
TW (1) TWI326598B (en)
WO (1) WO2008002544A2 (en)
ZA (1) ZA200708280B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (en) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 Temozolomide brain-targeting pharmaceutical composition and application thereof
CA3017631C (en) * 2016-03-21 2021-08-17 Duke University Sequential anti-cancer treatment
WO2018167627A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI276434B (en) * 1999-03-30 2007-03-21 Schering Corp Improved cancer treatment with temozolomide
AU2005304672B2 (en) * 2004-11-09 2010-03-11 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level

Also Published As

Publication number Publication date
JP2008534692A (en) 2008-08-28
TW200808803A (en) 2008-02-16
AR061618A1 (en) 2008-09-10
WO2008002544A2 (en) 2008-01-03
CN101309686A (en) 2008-11-19
NO20074913L (en) 2009-03-26
TWI326598B (en) 2010-07-01
KR20080015777A (en) 2008-02-20
AU2007221979A1 (en) 2008-01-10
CL2007001864A1 (en) 2008-02-08
AU2007221979A9 (en) 2008-01-10
CA2610439A1 (en) 2007-12-26
EP1901740A2 (en) 2008-03-26
KR20100055543A (en) 2010-05-26
ZA200708280B (en) 2009-03-25
WO2008002544A3 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
EA201100335A8 (en) PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-ASSOCIATED DISEASES
MX2011007397A (en) Dpp-iv inhibitors for treatment of diabetes in paediatric patients.
CO6361917A2 (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC PHARMACO
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
MY160041A (en) Compositions and methods for treating parasitic infections
MY161656A (en) Therapeutic use of diaminophenothiazines
AR073563A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED STATES
GT200800250A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
CL2012001405A1 (en) Spiroindolinone-pyrrolidine derived compounds; obtaining process; pharmaceutical composition; and use in the treatment or prophylaxis of cancer.
PH12013501790B1 (en) Use of dpp iv inhibitors
ECSP11010824A (en) TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN.
BRPI0919876A2 (en) Compound, pharmaceutical composition, use of a compound, and method for enhancing sleep quality, treating insomnia, and treating or controlling obesity in a mammalian patient in need thereof.
ATE551063T1 (en) USE OF BIFIDOBACTERIUM LONGUM FOR PROPHYLAXIS AND TREATMENT OF INFLAMMATION
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
GT201100118A (en) ARILO COMPOUNDS WITH HETEROCYCLIC SUBSTITUTES AS HIF INHIBITORS
BRPI0914678A8 (en) TOILET DISPENSING DEVICE AND PROCESS FOR DELIVERING A TREATMENT COMPOSITION TO A SANITARY DEVICE
BR112012013487A2 (en) AMANTADINE COMPOSITIONS AND METHODS OF USE
BRPI0710405B8 (en) racecadotril tablet, process of preparing a racecadotril tablet and use of racecadotril
MY150931A (en) Substituted oxazolidinones and their use
CL2008002545A1 (en) Phenoxy-benzyl-carbamoyl derived compounds; pharmaceutical composition; process for preparing the pharmaceutical composition; and its use in the treatment of pain.
EA200970885A1 (en) COMBINING CANCER TREATMENT WITH THE USE OF IL-18 PERSON AND ANTIBODY AGAINST CD20
BRPI0702847A (en) temozolomide unit dosage forms
NZ598124A (en) Compounds for treatment of inflammation
DK2155179T3 (en) Axomadol for pain management arthrosis
UA36366U (en) Method for treating catarrhal epiglottitis with unfavorable course and necrotic epiglottitis

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2228 DE 17/09/2013.